Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Depreciation & Amortization (CF) (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $160000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 50.16% year-over-year to $160000.0; the TTM value through Sep 2025 reached $910000.0, down 27.84%, while the annual FY2024 figure was $1.3 million, 6.41% down from the prior year.
  • Depreciation & Amortization (CF) reached $160000.0 in Q3 2025 per ZNTL's latest filing, roughly flat from $160000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $375000.0 in Q3 2022 and bottomed at $160000.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 4 years is $307733.3, with a median of $327000.0 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): rose 13.49% in 2024, then plummeted 51.07% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $326000.0 in 2022, then dropped by 11.35% to $289000.0 in 2023, then increased by 13.49% to $328000.0 in 2024, then crashed by 51.22% to $160000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $160000.0 in Q3 2025, $160000.0 in Q2 2025, and $262000.0 in Q1 2025.